@article {Pan2021.04.07.21253850, author = {Hongxing Pan and Jiankai Liu and Baoying Huang and Guifan Li and Xianyun Chang and Yafei Liu and Wenling Wang and Kai Chu and Jialei Hu and Jingxin Li and Dandan Zhu and Jingliang Wu and Xiaoyu Xu and Li Zhang and Meng Wang and Wenjie Tan and Weijin Huang and Fengcai Zhu}, title = {Immunogenicity and Safety of a SARS-CoV-2 Inactivated Vaccine (KCONVAC) in Healthy Adults: Two Randomized, Double-blind, and Placebo-controlled Phase 1/2 Clinical Trials}, elocation-id = {2021.04.07.21253850}, year = {2021}, doi = {10.1101/2021.04.07.21253850}, publisher = {Cold Spring Harbor Laboratory Press}, abstract = {Background The significant morbidity and mortality resulted from the infection of a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) call for urgent development of effective and safe vaccines. We report the immunogenicity and safety of a SARS-CoV-2 inactivated vaccine, KCONVAC, in healthy adults.Methods Two phase 1 and phase 2 randomized, double-blind, and placebo-controlled trials of KCONVAC were conducted in Chinese healthy adults aged 18 through 59 years. The phase 1 trial was conducted in a manner of dosage escalation. The first 30 participants were randomized in a ratio of 4:1 to receive two doses of either KCONVAC at 5 μg per dose or placebo on Day 0 and Day 14, and the second 30 participants were randomized to receive either KCONVAC at 10 μg per dose or placebo following the same procedures. The participants in the phase 2 trial were randomized in a ratio of 2:2:1 to receive either KCONVAC at 5 μg or 10 μg per dose, or placebo on Day 0 and Day 14, or Day 0 and Day 28. In the phase 1 trial, the primary safety endpoint was the proportion of participants experiencing adverse reactions/events within 28 days following each vaccination. Antibody response and cellular response were assayed in the phase 1 trial. In the phase 2 trial, the primary immunogenicity endpoint was the seroconversion and titre of neutralization antibody, and the seroconversion of receptor binding domain (RBD)-IgG 28 days after the second dose.Findings In the phase 1 trial, 60 participants were enrolled and received at least one dose of 5-μg vaccine (N=24), 10-μg vaccine (N=24), or placebo (N=12). In the phase 2 trial, 500 participants were enrolled and received at least one dose of 5-μg vaccine (N=100 for 0/14 or 0/28 regimens), 10-μg vaccine (N=100 for each regimen), or placebo (N=50 for each regimen). In the phase 1 trial, 13 (54\%), 11(46\%), and 7 (58\%) participants reported at least one adverse event (AE), of whom 10 (42\%), 6 (25\%), and 6 (50\%) participants reported at least one vaccination-related AE after receiving 5-μg vaccine, 10-μg vaccine, or placebo, respectively. In the phase 2 trial, 16 (16\%), 19 (19\%), and 9 (18\%) participants reported at least one AE, of whom 13 (13\%), 17 (17\%), and 6 (12\%) participants reported at least one vaccination-related AE after receiving 5-μg vaccine, 10-μg vaccine, or placebo at the regimen of Day 0/14, respectively. Similar results were observed in the three treatment groups of Day 0/28 regimen. All the AEs were grade 1 or 2 in intensity. No AE of grade 3 or more was reported. One SAE (foot fracture) was reported in the phase 1 trial. KCONVAC induced significant antibody response. 87{\textperiodcentered}5\% (21/24) to 100\% (24/24) of participants in the phase 1 trial and 83{\textperiodcentered}0\% (83/100) to 100\% (99/99) of participants in the phase 2 trial seroconverted for neutralising antibody to live virus, neutralising antibody to pseudovirus, and RBD-IgG after receiving two doses. Across the treatment groups in the two trials, the geometric mean titres (GMTs) of neutralising antibody to live virus ranged from 29{\textperiodcentered}3 to 49{\textperiodcentered}1 at Day 0/14 regimen and from 100{\textperiodcentered}2 to 131{\textperiodcentered}7 at Day 0/28 regimen, neutralising antibody to pseudovirus ranged from 69{\textperiodcentered}4 to 118{\textperiodcentered}7 at Day 0/14 regimen and from 153{\textperiodcentered}6 to 276{\textperiodcentered}6 at Day 0/28 regimen, and RBD-IgG ranged from 605{\textperiodcentered}3 to 1169{\textperiodcentered}8 at Day 0/14 regimen and from 1496{\textperiodcentered}8 to 2485{\textperiodcentered}5 at Day 0/28 regimen. RBD-IgG subtyping assay showed that a significant part of RBD-IgG was IgG1. The vaccine induced obvious T-cell response with 56{\textperiodcentered}5\% (13/23) and 62{\textperiodcentered}5\% (15/24) of participants in 5-μg and 10-μg vaccine groups showed positive interferon-γ enzyme-linked immunospot responses 14 days after the second dose in the phase 1 trial, respectively.Interpretation KCONVAC is well tolerated and able to induce robust antibody response and cellular response in adults aged 18 to 59 years, which warrants further evaluation with this vaccine in the upcoming phase 3 efficacy trial.Funding Guandong Emergency Program for Prevention and Control of COVID-19 (2020A1111340002) and Shenzhen Key Research Project for Prevention and Control of COVID-19.Competing Interest StatementJianL is an employee of Shenzhen Kangtai Biological Products. GL, XC, and YL are employees of Beijing Minhai Biotechnology. All other authors declare no competing interests.Clinical TrialThe studies were registered with ClinicalTrials.gov, number NCT04758273 and NCT04756323.Funding StatementGuandong Emergency Program for Prevention and Control of COVID-19 (2020A1111340002) and Shenzhen Key Research Project for Prevention and Control of COVID-19.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The studies were done in accordance with the Declaration of Helsinki and Good Clinical Practice. An independent data safety monitoring board was established before the start of the trials to provide oversight of the safety data during the studies. The protocols and informed consents were approved by the institutional review board of JPCDC.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesSupporting clinical documents including study protocol and statistical analysis plan will be available immediately following publication for at least 1 year. Researchers who provide a scientifically sound proposal will be allowed access to the individual participant data. Proposals should be directed to jszfc{at}vip.sina.com. These proposals will be reviewed and approved by the funder, investigator, and collaborators on the basis of scientific merit. To gain access, data requesters will need to sign a data access agreement.}, URL = {https://www.medrxiv.org/content/early/2021/04/08/2021.04.07.21253850}, eprint = {https://www.medrxiv.org/content/early/2021/04/08/2021.04.07.21253850.full.pdf}, journal = {medRxiv} }